{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:54:27Z","timestamp":1776279267816,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"am","delay-in-days":339,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009719","name":"Nancy Owens Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009719","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["BC130830"],"award-info":[{"award-number":["BC130830"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.clim.2019.02.011","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T12:19:48Z","timestamp":1551097188000},"page":"48-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Initial safety analysis of a randomized phase II trial of nelipepimut-S\u202f+\u202fGM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors"],"prefix":"10.1016","volume":"201","author":[{"given":"G. Travis","family":"Clifton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlin M.","family":"Peace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarrod P.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"Vreeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane F.","family":"Hale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garth S.","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer K.","family":"Litton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi K.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George E.","family":"Peoples","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mittendorf Elizabeth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2019.02.011_bb0005","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2019.02.011_bb0010","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2019.02.011_bb0015","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2019.02.011_bb0020","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.clim.2019.02.011_bb0025","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/07357907.2010.496759","article-title":"Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US","volume":"28","author":"Cronin","year":"2010","journal-title":"Cancer Investig."},{"issue":"20","key":"10.1016\/j.clim.2019.02.011_bb0030","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2019.02.011_bb0035","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMc0801440","article-title":"HER2 status and benefit from adjuvant trastuzumab in breast cancer","volume":"358","author":"Paik","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2019.02.011_bb0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13058-015-0643-7","article-title":"The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831","volume":"17","author":"Perez","year":"2015","journal-title":"Breast Cancer Res."},{"issue":"4 Suppl","key":"10.1016\/j.clim.2019.02.011_bb0045","volume":"78","author":"Fehrenbacher","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2019.02.011_bb0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ctrv.2017.10.005","article-title":"The clinical development of vaccines for HER2(+) breast cancer: current landscape and future perspectives","volume":"61","author":"Costa","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.clim.2019.02.011_bb0055","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1158\/1078-0432.CCR-07-1448","article-title":"Combined clinical trial results of a HER2\/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02","volume":"14","author":"Peoples","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2019.02.011_bb0060","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1078-0432.CCR-08-1126","article-title":"The impact of HER2\/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02","volume":"15","author":"Benavides","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2019.02.011_bb0065","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdu211","article-title":"Final report of the phase I\/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients","volume":"25","author":"Mittendorf","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2019.02.011_bb0070","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","article-title":"Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?","volume":"94","author":"Arnould","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.clim.2019.02.011_bb0075","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1245\/ASO.2006.03.069","article-title":"Investigating the combination of trastuzumab and HER2\/neu peptide vaccines for the treatment of breast cancer","volume":"13","author":"Mittendorf","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.clim.2019.02.011_bb0080","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1158\/0008-5472.CAN-16-2774","article-title":"Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells","volume":"77","author":"Gall","year":"2017","journal-title":"Cancer Res."},{"issue":"9 Suppl","key":"10.1016\/j.clim.2019.02.011_bb0085","article-title":"Abstract OT3-1-09: combination immunotherapy with trastuzumab and the HER2 vaccine E75 (nelipepimut-S) in high-risk HER2+ breast cancer patients to prevent recurrence","volume":"75","author":"Mittendorf","year":"2015","journal-title":"AACR"},{"key":"10.1016\/j.clim.2019.02.011_bb0090","doi-asserted-by":"crossref","first-page":"66192","DOI":"10.18632\/oncotarget.11751","article-title":"Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence","volume":"7","author":"Mittendorf","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clim.2019.02.011_bb0095","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2019.02.011_bb0100","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/annonc\/mdw150","article-title":"Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence","volume":"27","author":"Mittendorf","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2019.02.011_bb0105","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1200\/JCO.2008.20.6789","article-title":"Concurrent trastuzumab and HER2\/neu-specific vaccination in patients with metastatic breast cancer","volume":"27","author":"Disis","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2019.02.011_bb0110","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1245\/s10434-017-5844-0","article-title":"Results of a phase Ib trial of combination immunotherapy with a CD8+ T cell eliciting vaccine and trastuzumab in breast cancer patients","volume":"24","author":"Clifton","year":"2017","journal-title":"Ann. Surg. Oncol."},{"issue":"13 Suppl","key":"10.1016\/j.clim.2019.02.011_bb0115","article-title":"Abstract CT162: pre-specified interim analysis in a prospective, randomized phase II trial of trastuzumab vs trastuzumab+ NeuVax to prevent breast cancer recurrence in HER2+ breast cancer patients","volume":"77","author":"Peace","year":"2017","journal-title":"AACR"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618304637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618304637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:57:54Z","timestamp":1761494274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661618304637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":23,"alternative-id":["S1521661618304637"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2019.02.011","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial safety analysis of a randomized phase II trial of nelipepimut-S\u202f+\u202fGM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2019.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}